Atrium Therapeutics Estimates $293.6 Million Will Fund Operations Through 2028
The heart-drug developer expects initial human trial results in 2027 as research and administrative costs rise.
Atrium Therapeutics, which is testing RNA treatments for genetic heart disease, estimated Thursday that its $293.6 million financing-adjusted cash balance will fund operations through 2028. The estimate in its SEC earnings filing extends beyond the company's expected initial human trial results in the second half of 2027.
The Cash Behind The Trial
Atrium held $232.1 million in cash and short-term investments at September's end. Its financing-adjusted estimate adds receipt of a $15.0 million Bristol Myers Squibb collaboration milestone announced in August and net proceeds from the $50 million private placement that closed in October.
Brendan Winslow, Atrium's chief financial officer, said, "Our $50 million private placement with leading institutional investors extends our cash runway through 2028."
Third-quarter collaboration revenue rose to $15.3 million from $12.3 million a year earlier. Atrium attributed most of the revenue to the Bristol Myers Squibb milestone; research services supplied the remainder.
Research spending increased to $13.8 million from $9.7 million. Atrium tied the spending primarily to its Corventis trial, manufacturing, work needed before human testing of ATR 1086 and expansion of its research capabilities.
Administrative costs rose to $8.2 million from $2.8 million, which Atrium attributed to personnel, professional fees and expanded operations. The quarterly net loss widened to $4.3 million, or $0.25 per share, from $37,000, or $0.00 per share.
Testing The Genetic Cause
Atrium announced on October 27 that the first participant received ATR 1072 in Corventis. The early-to-mid-stage study plans to enroll approximately 37 people with PRKAG2 syndrome, first assessing escalating doses and then evaluating a selected dose in an expanded group.
PRKAG2 syndrome causes glycogen to accumulate abnormally in the heart, thickens heart muscle and disrupts electrical conduction. Current care treats symptoms; no approved medicine addresses the genetic cause. Atrium described Corventis as the first clinical trial aimed at that cause.
Recent animal findings provide the rationale for human testing. A mouse-specific version of ATR 1072 reversed glycogen accumulation, reduced heart weight and left ventricular wall thickness, and improved electrical-conduction measures. Atrium cautioned that human trial outcomes may differ from animal results.
Atrium also plans to seek permission in 2027 to test ATR 1086 in people with PLN cardiomyopathy. That genetic disease can cause abnormal protein deposits and raises the risk of heart failure and sudden cardiac death; no approved therapy targets its molecular cause. The company is advancing two additional rare-cardiomyopathy research programs and plans to select its next development candidate in 2027.
Atrium expects the first Corventis results in the second half of 2027—the next scheduled evidence of how ATR 1072 performs in people.
Sources
- 8-K Filing — Atrium Therapeutics, Inc. (RNA) — SEC EDGAR
- Exhibit d692180dex991.htm — Atrium Therapeutics, Inc. 8-K exhibit — SEC EDGAR
- Atrium Therapeutics Reports Third Quarter 2026 Financial Results — prnewswire.com
- 8-K filed 2026-10-27 — Atrium Therapeutics, Inc. (earlier disclosure) — SEC EDGAR